Intelligence Profile
Research Papers
Research Papers and Clinical Trials
The research on Low-Dose Naltrexone (LDN) encompasses several recent studies and clinical trials examining its potential therapeutic applications across various conditions.
Key Clinical Trials
The INNOVA Study represents one of the most significant recent investigations - a 12-month randomized, double-blind, placebo-controlled trial examining LDN efficacy in women with fibromyalgia syndrome. This single-center study was published in the European Journal of Pain in 2026, though specific sample size and detailed results are not provided in the available evidence.
Another completed fibromyalgia study, The FINAL Study (NCT04270877), was a Phase 2 trial specifically investigating LDN for fibromyalgia patients. The study has been completed, but results details are not available in the current evidence.
A randomized, double-blind, placebo-controlled study examined LDN as an adjunctive treatment for major depressive disorder, using a hybrid parallel-arm design. This 2026 study was published in Frontiers in Pharmacology, though sample size and specific outcomes are not detailed in the available abstracts.
Ongoing Research
Several Phase 2 trials are currently recruiting or recently completed, including studies on:
- Vulvodynia treatment (NCT05955313) - currently recruiting patients
- COVID-19 outcomes when combined with colchicine (NCT04756128) - completed Phase 2 trial
- Pediatric Crohn's disease (NCT00715117) - completed Phase 2 study
Review Literature
A 2026 narrative review in Advances in Therapy examined the overall evidence base for LDN, while another review in the Journal of Personalized Medicine focused specifically on LDN's mechanisms and clinical implications in chronic pain management. A broader 2026 review in Clinical and Experimental Rheumatology covered therapeutic advances in fibromyalgia, including LDN.
Preclinical Research
Laboratory studies have explored LDN's mechanisms, including research on vascular endothelial growth factor and astrocyte responses in diabetic mouse models following brain injury, and combination therapy approaches with other compounds for addiction treatment.
Evidence Limitations: While multiple studies have been conducted, the available abstracts do not provide detailed sample sizes, specific outcome measures, or effect sizes for most trials. The evidence base appears to be growing but remains limited in scope for definitive clinical recommendations.
This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for personalized treatment decisions.